Tag Archives: BIO CEO & Investor Conference

Buy Side Investors Bullish Ahead of 2014 BIO CEO & Investor Conference

CEO2014_blog copy

2013 was a record year for the biotech sector, with the NASDAQ Biotechnology Index hitting record highs again and again, ending the year up over 60% — beating the S&P 500 more than two-fold.   But what can we expect for 2014? That will be the topic of discussion at our opening plenary panel at next week’s BIO CEO & Investor Conference, taking place Monday and Tuesday, February 10-11 in New York. To help spur Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO CEO: Five Prime Therapeutics Company Snapshot

fiveprime

Five Prime Therapeutics is another company that will be presenting at next week’s BIO CEO & Investor Conference. They will be among 20 other presenters at the event who debuted an IPO in the last two years. Read below to learn more about their work, and what to expect from them at the event. Company Snapshot What is your company’s lead product or technology? Five Prime focuses on discovering and developing novel protein therapeutics for Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

tetraphase

The BIO CEO & Investor Conference is now just a week away, and buzz for the event has never been greater. Tomorrow, Inside BIO is hosting its first ever twitter chat to discuss the annual buyside survey, which has been getting great responses from the investor community. Presentation spots are still sold out as well, and we’re continuing to highlight those companies slated to present. One such company is Tetraphase Pharmaceuticals, who went public this Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,